Breast Reconstruction Meshes Market Report 2025

The breast reconstruction market size has grown strongly in recent years. It will grow from $0.57 billion in 2024 to $0.61 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to the rising incidence of breast cancer, increased demand for mastectomy surgeries, greater awareness of reconstruction options, expansion of hospital-based reconstruction services, and a growing number of breast implant revision procedures.

The breast reconstruction market size is expected to see strong growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The projected growth in the forecast period can be attributed to an increasing preference for prepectoral reconstruction, a rise in breast reconstruction surgeries, improved healthcare access in developing regions, the expansion of cosmetic surgery clinics, and greater adoption of biological and hybrid meshes. Key trends expected during this period include technological improvements in mesh design, innovations in absorbable and hybrid mesh materials, increased investment in research and development, the emergence of 3D-printed reconstruction scaffolds, and progress in minimally invasive reconstruction methods.

The rising incidence of breast cancer is expected to drive the growth of the breast reconstruction meshes market in the coming years. Breast cancer is a malignant condition characterized by the uncontrolled growth of abnormal cells in breast tissue, which can spread to other parts of the body if not detected and treated early. The rate of breast cancer is increasing significantly, partly because more women are delaying childbirth and having fewer children, which affects hormone levels over time and raises their risk of developing the disease. Breast reconstruction meshes aid in managing breast cancer by providing structural support and helping to shape and stabilize the breast during reconstructive surgery after a mastectomy, thereby improving both surgical results and cosmetic appearance. For example, in February 2025, the World Health Organization, a Switzerland-based intergovernmental agency, reported approximately 2.3 million new breast cancer cases and 670,000 related deaths worldwide in 2022. These figures are projected to increase to 3.2 million new cases and 1.1 million deaths annually by 2050. Therefore, the increasing incidence of breast cancer is contributing to the growth of the breast reconstruction meshes market.

Key companies in the breast reconstruction mesh market are concentrating on securing regulatory approvals to broaden their product lines, improve market access, and enhance their competitive edge. Regulatory approvals are official endorsements from government bodies confirming that a product meets necessary safety, quality, and compliance standards before it can be marketed or used. For instance, in October 2022, the Plastic Surgery Foundation, a US-based charitable organization, received approval from the Food and Drug Administration (FDA) to conduct a prospective, multicenter observational study assessing the use of acellular dermal matrix (ADM) and surgical mesh in implant-based breast reconstruction. This study aims to generate robust evidence regarding the safety, effectiveness, surgical techniques, complications, device loss, and patient satisfaction related to these devices, which are currently used off-label in breast reconstruction without formal FDA approval for this purpose. The trial will not require surgeons to change their standard practices or randomize patients, reflecting real-world use, and will include control groups without ADM or mesh for comparison.

In February 2024, RTI Surgical, a US-based medical technology firm, acquired Cook Biotech Incorporated for an undisclosed sum. Through this acquisition, RTI Surgical aims to bolster its position as a leading contract development and manufacturing organization (CDMO) in regenerative medicine by expanding its diverse portfolio of allograft and xenograft biomaterials, gaining access to new clinical areas, and enhancing its expertise, scale, and flexibility across end-to-end services to improve patient outcomes. Cook Biotech Incorporated is a US-based biotechnology company specializing in producing breast reconstruction meshes and advanced biologic scaffolds for surgical tissue repair.

Major players in the breast reconstruction meshes market are Stryker Corporation, Baxter International Inc., Coloplast A/S, Integra LifeSciences Holdings Corporation, MTF Biologics, LifeNet Health, Silimed Indústria de Implantes Ltda., AlloSource, TELA Bio Inc., GC Aesthetics Ltd., pfm medical AG, POLYTECH Health & Aesthetics GmbH, CollPlant Biotechnologies Ltd., Laboratoires Arion, Advanced Biomedical Concept Srl, Dipromed Srl, Meccellis Biotech SAS, Novus Scientific AB, SERAG-WIESSNER GmbH & Co. KG, BellaSeno GmbH, RTI Surgical Holdings Inc.

North America was the largest region in the breast reconstruction market in 2024. Asia‑Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in breast reconstruction meshes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the breast reconstruction meshes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The breast reconstruction meshes market consists of sales of 3D-printed meshes, acellular dermal matrices, hybrid composite meshes, scaffold-based implants, and tissue regeneration meshes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The breast reconstruction meshes market research report is one of a series of new reports that provides breast reconstruction meshes market statistics, including breast reconstruction meshes industry global market size, regional shares, competitors with a breast reconstruction meshes market share, detailed breast reconstruction meshes market segments, market trends and opportunities, and any further data you may need to thrive in the breast reconstruction meshes industry. This breast reconstruction meshes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Breast reconstruction meshes are medical implants utilized during breast reconstruction procedures to offer support and structural stability to breast tissue or implants. Commonly employed following mastectomy (breast removal), these meshes assist in shaping and securing the reconstructed breast. Acting as scaffolds, they integrate with the patient’s tissue, promoting proper healing, positioning, and aesthetic results.

The primary categories of breast reconstruction meshes include synthetic mesh and biological mesh. Synthetic mesh is a surgical material composed of synthetic polymers, specifically designed to deliver structural reinforcement and stability during reconstruction surgeries. These meshes are available in different forms, such as absorbable, nonabsorbable, resorbable surgical mesh, and nonresorbable surgical mesh. They are used in a variety of procedures, including implant-based reconstruction, autologous tissue reconstruction, prepectoral and subpectoral reconstruction, revision surgeries, and correction of congenital asymmetry or deformities. The main end users include hospitals, ambulatory surgical centers, specialty clinics, comprehensive cancer centers, plastic surgery clinics, and academic and research institutions.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.